AI, Biology, and Biosecurity in the Age of Acceleration | Stanford's RAISE Health Symposium 2026

Why It Matters

Because AI can simultaneously accelerate drug discovery and enable creation of weapons of mass harm, inadequate oversight threatens public health, national security, and trust in science.

Key Takeaways

• AI is a dual‑use technology with profound biosecurity risks.
• Past Asilomar model fails for AI due to rapid, global diffusion.
• AI can design novel antibiotics and also create lethal toxins.
• Governance must combine top‑down controls, adaptive oversight, and public involvement.
• Closing cultural lag may require slowing AI rollout or faster regulation.

Summary

At Stanford’s RAISE Health Symposium 2026, speakers warned that artificial intelligence, now a general‑purpose technology, is also a dual‑use tool that can transform both medicine and biological weapons.

The presenter contrasted AI’s rapid, worldwide diffusion with the 1975 Asilomar meeting on recombinant DNA, noting that the old consensus‑building model cannot contain today’s AI. While AI‑driven models have already identified promising new antibiotics from archaea, the same systems can design potent nerve agents, synthesize pandemic pathogens, and poison scientific literature.

Examples cited included a toxicity‑trained model that suggested compounds surpassing VX, an AI tutorial that taught non‑scientists how to acquire a viral agent, and Stanford researcher Brian He’s genome‑language model that built functional bacteriophages—demonstrating both therapeutic promise and the ease with which malicious actors could replicate the work.

The speaker argued that without a robust, adaptive governance framework—combining top‑down regulation, bottom‑up oversight, access controls, and genuine public deliberation—society faces a widening cultural lag. Slowing AI deployment or accelerating policy responses is essential to prevent catastrophic biosecurity outcomes while preserving legitimate medical advances.

Original Description

How does AI transform both the opportunity and the risk in biological research, and what are the most pressing issues facing the industry today?

David Relman, Professor of Microbiology and Immunology, Stanford School of Medicine

The 2026 RAISE Health Symposium convened leaders from science, medicine, technology, and policy explored the state of AI in biomedicine and what it will take to deploy these technologies responsibly to advance discovery, support clinicians, and improve patient health. Presented by Stanford Medicine and Stanford HAI:

https://med.stanford.edu/raisehealth/events/healthaiweek/2026symposium.html

Stanford Medicine: https://med.stanford.edu/news.html

Stanford Institute for Human-Centered AI (HAI): https://hai.stanford.edu

#AIinHealth #AIinMedicine #ResponsibleAI #FutureOfMedicine

Stanford Medicine advances human health through world-class biomedical research, education and patient care. Bringing together the resources of Stanford University School of Medicine, Stanford Health Care and Lucile Packard Children's Hospital, Stanford Medicine is committed to training future leaders in biomedicine and translating the latest discoveries into new ways to prevent, diagnose and treat disease.

The Stanford Medicine YouTube channel is a curated collection of contributions from our School of Medicine departments, divisions, students, and the community. Our diverse content includes coverage of events, presentations, lectures, and associated stories about the people of Stanford Medicine.